FDA Classification Setback Bodes Well For Wound Care Cos.
In MiMedx Group Inc. v. U.S. Food and Drug Administration,[1] the U.S. District Court for the Northern District of Georgia on Sept. 21 handed the regenerative medicine industry a significant win, vacating...To view the full article, register now.
Already a subscriber? Click here to view full article